About: Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Latest price: $4.94 (+1.86%)
PASGNASDAQPassage Bio Inc
Passage Bio Inc share price
PASG price activity
Last Price
$4.940
Change (24hr)
0.09 USD (1.86%)
Volume
197.01K
Volume (4w avg)
-
Open
$4.84
Day Range
$4.74 - $5.36
Previous Close
$4.85
Last Trade
09 Sep, 8:00 pm GMT+0
Delayed
09 Sep, 8:00 pm GMT+0
PASG price performance
Delayed
09 Sep, 8:00 pm GMT+0
PASG Market Signals